Financial Report: Novartis

Novartis

3Q Revenues: $14.3 billion (+4%)

3Q Earnings: $2.3 billion (-6%)

YTD Revenues: $42.8 billion (+2%)

YTD Earnings: $7.2 billion (-2%)

Comments: Pharmaceutical sales were $7.9 billion in the quarter, up 1%, offset by generic competition for Diovan (-14% to $835 million). Oncology sales were $2.7 billion, up 2%, driven by Afinitor (+65% to $337 million), Tasigna (+25% to $315 million), Exjade (+9% to $212 million) and Sandostatin (+7% to $401 million), offset by Zometa (-66% to $104 million). The Primary Care franchise was up 7% to $1.8 billion driven by continued strong uptake of Galvus (+46% to $316 million) and Exforge (+11% to $359 million). The Neuroscience franchise was up 25% to $0.9 billion with growth from Gilenya (+63% to $518 million). The Ophthalmics franchise was down 2% to $0.6 billion, impacted by Lucentis (-1% to $581 million), which had a negative pricing impact. Sandoz sales were up 11% to $2.3 billion in the quarter. Alcon sales were up 3% to $2.5 billion.